Larimar Therapeutics (NASDAQ:LRMR) Hits New 1-Year High Following Analyst Upgrade

Larimar Therapeutics, Inc. (NASDAQ:LRMR)’s share price reached a new 52-week high during trading on Wednesday after Lifesci Capital upgraded the stock to a strong-buy rating. The stock traded as high as $6.42 and last traded at $6.00, with a volume of 63963993 shares. The stock had previously closed at $3.69.

LRMR has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Larimar Therapeutics in a research note on Thursday, January 22nd. Leerink Partners raised shares of Larimar Therapeutics to a “strong-buy” rating in a report on Monday, January 5th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $16.50.

Trending Headlines about Larimar Therapeutics

Here are the key news stories impacting Larimar Therapeutics this week:

• Positive Sentiment: FDA granted Breakthrough Therapy Designation for nomlabofusp in Friedreich’s ataxia; Larimar reiterated plans to submit a BLA in June 2026 with topline open‑label data expected Q2 2026 and a potential U.S. launch in H1 2027 — this materially raises the drug’s regulatory and commercial prospects. Press release: Larimar Announces FDA Breakthrough Therapy Designation
• Positive Sentiment: Analyst support picked up: Wedbush reaffirmed an “outperform” rating and placed an $11 price target (roughly +85% from the pre-news level cited), which can validate upside expectations and attract momentum buyers. Benzinga
• Positive Sentiment: Lifesci Capital upgraded LRMR to a “strong-buy”, adding further buy-side signals that can support continued inflows from retail and institutional investors. Zacks.com
• Positive Sentiment: Unusual options activity: traders bought ~3,744 call contracts (≈+456% vs. typical daily call volume), indicating speculative bullish positioning that often accompanies rapid share-price rallies and can amplify short‑term volatility and buying pressure.
• Neutral Sentiment: Broad media coverage and explanatory articles explaining the FDA designation and share surge have increased visibility and may attract additional speculative interest. Investing.com: Larimar stock surges on FDA breakthrough status
• Neutral Sentiment: Multiple outlets summarized the move and drivers (MSN, AAII), which helps explain the rally to a wider audience but does not itself change fundamentals. MSN: Larimar surges on FDA breakthrough status

Hedge Funds Weigh In On Larimar Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in LRMR. BNP Paribas Financial Markets increased its stake in Larimar Therapeutics by 75.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 10,146 shares of the company’s stock valued at $33,000 after purchasing an additional 4,376 shares in the last quarter. Savant Capital LLC bought a new stake in Larimar Therapeutics in the second quarter valued at about $39,000. B.O.S.S. Retirement Advisors LLC acquired a new position in shares of Larimar Therapeutics during the third quarter valued at $41,000. Coldstream Capital Management Inc. acquired a new position in Larimar Therapeutics in the 3rd quarter worth approximately $57,000. Finally, Wealth Enhancement Advisory Services LLC boosted its position in shares of Larimar Therapeutics by 33.9% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 18,248 shares of the company’s stock worth $59,000 after buying an additional 4,619 shares during the period. 91.92% of the stock is owned by hedge funds and other institutional investors.

Larimar Therapeutics Price Performance

The firm has a market cap of $512.81 million, a PE ratio of -3.21 and a beta of 1.01. The business has a fifty day moving average price of $3.44 and a two-hundred day moving average price of $3.76.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.